(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5R)-3,4,5-Trihydroxyoxan-2-yl]oxy-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-2,3,4-triol

Term ID

CHEBI:150788

Synonyms

beta-D-xylo-pentopyranosyl-(1->4)-[alpha-L-arabino-pentopyranosyl-(1->6)]-beta-D-gluco-hexopyranose
Xyl(b1-4)[Ara(a1-6)]b-Glc

Definition

References

glytoucan:G43060JV

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5R)-3,4,5-Trihydroxyoxan-2-yl]oxy-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-2,3,4-triol

Phenotype where environments contain (2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5R)-3,4,5-Trihydroxyoxan-2-yl]oxy-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-2,3,4-triol

Phenotype modified by environments containing (2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5R)-3,4,5-Trihydroxyoxan-2-yl]oxy-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-2,3,4-triol

Phenotype affecting (2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5R)-3,4,5-Trihydroxyoxan-2-yl]oxy-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-2,3,4-triol

Human Disease Model